Manuel Scimeca is a Researcher in Biotechnology and methods in Laboratory Medicine at the University of Rome “Tor Vergata”. He obtained his Ph.D. (2015) in Medical Biotechnology and Translational Medicine studying the role of microcalcifications in breast cancer occurrence and progression. During his postdoctoral activity, he specialized in developing electron microscopy applications (EDX microanalysis, immunogold labeling) for studying the impact of environmental pollution, mainly toxic metals, on the pathogenesis of degenerative diseases such as cancer and atherosclerosis. Fields of research also include the identification of reliable innovative therapeutic targets for neoplastic diseases, the study of chemical/physical properties of ectopic calcifications in cancer and atheromatic lesions, and the characterization of the pathogenesis of carotid atherosclerotic lesions. He is co-founder of the university spin-off TMALab s.r.l. and the company ORCHIDEALab s.r.l.